Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web: www.sanofi.com
Capitalization:
  • Market Cap: $123.80604 billion
  • Outstanding Shares: 2,511,508,000
Average Prices:
  • 50 Day Moving Avg: $48.38
  • 200 Day Moving Avg: $47.45
  • 52 Week Range: $36.81 - $50.24
P/E:
  • Trailing P/E Ratio: 11.45
  • Foreward P/E Ratio: 14.35
  • P/E Growth: 1.90
Sales & Book Value:
  • Annual Revenue: $43.43 billion
  • Price / Sales: 2.84
  • Book Value: $27.45 per share
  • Price / Book: 1.79
Dividend:
  • Annual Dividend: $1.10
  • Dividend Yield: 2.2%
Profitability:
  • EBIDTA: $13.03 billion
  • Net Margins: 25.89%
  • Return on Equity: 25.34%
  • Return on Assets: 14.17%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.16%
Misc:
  • Average Volume: 1.23 million shs.
  • Beta: 0.88
  • Short Ratio: 1.35
 

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, February 17th. Stockholders of record on Monday, May 15th will be paid a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date is Thursday, May 11th. This is a boost from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) announced its earnings results on Monday, July, 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.74. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company's revenue was down 2.3% on a year-over-year basis. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

12 analysts have issued 1 year target prices for Sanofi's shares. Their forecasts range from $52.00 to $55.00. On average, they expect Sanofi's share price to reach $53.50 in the next year. View Analyst Ratings for Sanofi.

What are analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:

  • 1. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)
  • 2. According to Zacks Investment Research, "Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas. Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. New drugs like Aubagio and Lemtrada are likely to continue doing well.  We are also optimistic on sales prospects of Dupixent, which could prove to be an important growth driver. The recent FDA approval of Kevzara for rheumatoid arthritis is also encouraging. Sanofi’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of new products like Praluent. At the Q1 conference call, management warned that the US diabetes sales will decline faster through 2017." (6/2/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Who owns Sanofi stock?

Sanofi's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dodge & Cox (2.50%), Franklin Resources Inc. (0.83%), Fisher Asset Management LLC (0.54%), Boston Partners (0.32%), Hotchkis & Wiley Capital Management LLC (0.23%) and FMR LLC (0.21%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Dodge & Cox, Hotchkis & Wiley Capital Management LLC, Wells Fargo & Company MN, Federated Investors Inc. PA, Boston Partners, Macquarie Group Ltd., Northern Trust Corp and Tekla Capital Management LLC. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was acquired by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Fisher Asset Management LLC, BlackRock Inc., Janus Henderson Group PLC, FMR LLC, Harbour Capital Advisors LLC, Aperio Group LLC and Schafer Cullen Capital Management Inc.. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $49.08.


MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $53.50 (9.01% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
8/30/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
8/1/2017Cowen and CompanyReiterated RatingMarket Perform$46.00 -> $52.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017        
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.24%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:28.06% (Trailing 12 Months of Earnings)
33.13% (Based on This Year's Estimates)
32.16% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017annual$1.583.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.33%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
Source:
DateHeadline
seekingalpha.com logoSanofi (SNY) Presents At Bank of America Merrill Lynch 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 19 at 7:55 AM
americanbankingnews.com logoAceto Corporation (ACET) and Sanofi (SNY) Head to Head Survey
www.americanbankingnews.com - September 18 at 6:40 PM
finanznachrichten.de logoSanofi: Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
www.finanznachrichten.de - September 17 at 8:03 AM
americanbankingnews.com logoJ P Morgan Chase & Co Reaffirms Neutral Rating for Sanofi SA (SNY)
www.americanbankingnews.com - September 15 at 2:34 PM
nasdaq.com logoSanofi Reports Results Of TAKE CONTROL Study - Quick Facts - Nasdaq
www.nasdaq.com - September 14 at 10:26 AM
streetinsider.com logoSanofi (SNY) Says New Post-hoc Analysis Shows Soliqua 100/33 Provided Earlier Blood Sugar Control than Insulin ... - StreetInsider.com
www.streetinsider.com - September 14 at 10:26 AM
americanbankingnews.com logoReviewing Sanofi (SNY) & Eyegate Pharmaceuticals (EYEG)
www.americanbankingnews.com - September 14 at 12:26 AM
finance.yahoo.com logoRegeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
finance.yahoo.com - September 12 at 10:01 AM
nasdaq.com logoSanofi Reports Post-hoc Analysis Of Phase 3 Soliqua 100/33 Trials
www.nasdaq.com - September 12 at 10:01 AM
finance.yahoo.com logoFeatured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA
finance.yahoo.com - September 12 at 10:01 AM
feeds.benzinga.com logoMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
feeds.benzinga.com - September 11 at 9:23 AM
feeds.benzinga.com logoSanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
feeds.benzinga.com - September 11 at 2:58 AM
americanbankingnews.com logoSanofi (SNY) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 9 at 6:45 PM
seekingalpha.com logoRegeneron and Sanofi's cemiplimab a Breakthrough Therapy for type of skin cancer
seekingalpha.com - September 9 at 8:40 AM
finance.yahoo.com logo[$$] Sanofi Stops Work on Two Zika Vaccines
finance.yahoo.com - September 9 at 8:40 AM
streetinsider.com logoRegeneron (REGN) & Sanofi (SNY) Granted FDA Breakthrough Designation for Cemiplimab (REGN2810), Advanced ... - StreetInsider.com
www.streetinsider.com - September 8 at 8:34 AM
finanznachrichten.de logoSanofi: Sanofi Alliance Partner Alnylam Gives Update on Fitusiran
www.finanznachrichten.de - September 7 at 9:12 AM
finance.yahoo.com logoSanofi Has Good Potential Upside
finance.yahoo.com - September 7 at 9:12 AM
feeds.benzinga.com logoSanofi Alliance Partner Alnylam Gives Update on Fitusiran
feeds.benzinga.com - September 7 at 8:20 AM
seekingalpha.com logoSanofi stops work on Zika vaccines
seekingalpha.com - September 7 at 3:04 AM
feeds.benzinga.com logoSanofi rated AA by Scope Ratings
feeds.benzinga.com - September 7 at 2:40 AM
seekingalpha.com logoFDA tentatively OKs Sanofi's fast-acting insulin Admelog; shares up 1%; Lilly down 2%
seekingalpha.com - September 2 at 8:54 AM
streetinsider.com logoSanofi (SNY) Reports Tentative FDA Approval of Admelog 100 Units/mL
www.streetinsider.com - September 2 at 8:54 AM
americanbankingnews.com logoSanofi (SNY) Rating Reiterated by Argus
www.americanbankingnews.com - September 1 at 8:20 PM
americanbankingnews.com logoSanofi (SNY) Upgraded to "Hold" by HSBC Holdings plc
www.americanbankingnews.com - August 30 at 7:32 PM
americanbankingnews.com logoFinancial Review: Sanofi (SNY) & Johnson & Johnson (JNJ)
www.americanbankingnews.com - August 29 at 10:28 PM
fool.com logo3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
www.fool.com - August 29 at 8:08 AM
finanznachrichten.de logoSanofi: Sanofi completes the acquisition of Protein Sciences
www.finanznachrichten.de - August 28 at 6:35 AM
feeds.benzinga.com logoSanofi completes the acquisition of Protein Sciences
feeds.benzinga.com - August 28 at 2:40 AM
americanbankingnews.com logoInsider Buying: Sanofi (SNY) Major Shareholder Buys 60,595 Shares of Stock
www.americanbankingnews.com - August 25 at 7:22 PM
americanbankingnews.com logoSanofi (SNY) Major Shareholder Sanofi Buys 105,820 Shares
www.americanbankingnews.com - August 25 at 7:22 PM
finance.yahoo.com logoJanuvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17
finance.yahoo.com - August 25 at 11:51 AM
finance.yahoo.com logoCan Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17?
finance.yahoo.com - August 24 at 12:59 PM
americanbankingnews.com logoCoLucid Pharmaceuticals (CLCD) versus Sanofi (SNY) Critical Review
www.americanbankingnews.com - August 21 at 6:16 PM
finance.yahoo.com logoSanofi Genzyme Continues Driving Revenue Growth in 2Q17
finance.yahoo.com - August 18 at 7:21 AM
finance.yahoo.com logoEuropean Pharma Companies Slip on MS Pricing Probe
finance.yahoo.com - August 18 at 7:21 AM
cnbc.com logoSen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers
www.cnbc.com - August 17 at 6:17 PM
latimes.com logoEpiPen maker settles: It'll pay less than what it got by allegedly overcharging
www.latimes.com - August 17 at 5:27 PM
finance.yahoo.com logoETFs with exposure to Sanofi : August 16, 2017
finance.yahoo.com - August 17 at 7:46 AM
finance.yahoo.com logoSanofi’s Revenue Growth in 2Q17
finance.yahoo.com - August 17 at 7:46 AM
americanbankingnews.com logoSanofi (SNY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 15 at 10:46 PM
seekingalpha.com logoSanofi's Zika Standoff: Bad Medicine? - Seeking Alpha
seekingalpha.com - August 11 at 8:40 AM
streetinsider.com logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - StreetInsider.com
www.streetinsider.com - August 9 at 7:40 AM
streetinsider.com logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - StreetInsider.com
www.streetinsider.com - August 9 at 7:40 AM
seekingalpha.com logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha
seekingalpha.com - August 9 at 7:40 AM
seekingalpha.com logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha
seekingalpha.com - August 9 at 7:40 AM
finance.yahoo.com logoThis Week's Pharma, Energy IPOs
finance.yahoo.com - August 8 at 6:59 AM
americanbankingnews.com logoSanofi (SNY) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - August 5 at 5:30 PM
seekingalpha.com logoRegeneron to terminate antibody discovery partnership with Sanofi at year-end - Seeking Alpha
seekingalpha.com - August 4 at 8:22 AM
seekingalpha.com logoSanofi Q2/2017: Mixed Signals - Seeking Alpha
seekingalpha.com - August 4 at 8:22 AM

Social

Chart

Sanofi (SNY) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff